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Abstract Cellular prion (PrPc) is a plasma membrane glyco-
syphosphatidylinositol-anchored protein present in neurons but
also in other cell types. Protein conservation among species
suggests that PrPc may have important physiological roles.
Cellular and molecular approaches have established several novel
features of the regulation of PrPc expression, cellular trafficking
as well as its participation in copper uptake, protection against
oxidative stress, cell adhesion, differentiation, signaling and cell
survival. It is therefore likely that PrPc plays pleiotropic roles
in neuronal and non-neuronal cells, and as such the loss of
function of PrPc may be an important component of various
diseases. ß 2002 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
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1. Introduction
The cellular prion protein (PrPc) was identi¢ed not because
of its cellular function but rather due to its involvement in
neurodegenerative diseases called spongiform encephalopa-
thies [1]. Based on previous approaches to viral oncogenes,
scientists were looking for an organism that coded a new
type of protein responsible for cellular changes. The surprise
was that, in fact, the molecule identi¢ed was coded by the
cellular genome.
It is believed that the infectious particles, responsible for the
transmissible forms of prion diseases are composed by a single
protein, that is a PrPc isoform with only a distinct secondary
structure. Therefore, it was proposed that infectivity is a con-
sequence of conformational modi¢cation of PrPc by the in-
fectious protein prion scrapie (PrPsc) [1]. Due to the uncom-
mon characteristics of these diseases, e¡orts were mainly di-
rected at understanding the infection, while the physiological
roles of PrPc were mostly ignored.
Herein we report several aspects of PrPc gene expression,
regulation and tra⁄cking. We also discuss interactions be-
tween PrPc and the extracellular matrix glycoprotein laminin
[2,3] as well as properties of a peptide predicted to mimic the
docking site of a putative PrPc membrane ligand (p66) [4].
Such interactions elicit signal transduction via PrPc, which
can lead both to neuroprotection (Chiarini et al., J. Biol.
Chem., in press) and neuronal di¡erentiation [2,3]. In addi-
tion, the role of copper binding [5] in the internalization of
PrPc [6,7] is discussed.
2. PrPc expression regulation
Prn-p (the gene that codes for PrPc) contains three exons in
mouse and rat and two exons in hamster and humans, with
the third and second exons, respectively, encoding the entire
protein of approximately 250 amino acids. Two signal pep-
tides are present in the molecule, one at the N-terminus,
which is cleaved during the biosynthesis of PrPc in the rough
endoplasmic reticulum and the second at the C-terminus, that
allows for attachment to a glycosyphosphatidylinositol (GPI)
anchor. Two glycosylation sites are also mapped to the
C-terminus (reviewed in [1]).
It was believed that Prn-p is a housekeeping gene, since its
mRNA is constitutively expressed in tissues from adult ani-
mals [8]. However, PrPc expression is highly regulated both
during development [9] and by nerve growth factor (NGF) [2].
Regulation of PrPc levels is associated both with a physiolog-
ical function [2] and with the rate of prion infection [10].
The Prn-p gene promoter has been identi¢ed in mouse [11],
hamster [12], rat [13], cattle [14] and human [15], and the
major region of transcriptional control was found upstream
of the initiation site. However, other regulatory regions were
also identi¢ed [11,14]. All reported Prn-p promoters lack a
TATA box and contain GC-rich features, which are potential
binding sites for Sp-1 transcriptional factors. Speci¢c sites for
AP-1 and AP-2 were also identi¢ed [11,13,15]. However, it is
believed that these ubiquitous transcription factors cannot
account for tissue speci¢c regulation in adult animals [8].
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It is tempting to speculate that Prn-p promoter activity may
be controlled by tissue speci¢c transcription factors, but either
promoter methylation or changes in chromatin structure may
also occur. It is important to note that transcriptional repres-
sion can be mediated by histone deacetylase 1 targeting to Sp-
1 [16], whose binding element is present in all described Prn-p
promoters. In fact, we have observed that Prn-p promoter
activity is highly dependent on chromatin structure (Cabral
et al., J. Biol. Chem., in press), indicating that PrPc expression
may be regulated.
3. Cellular tra⁄c of PrPc
Internalization of PrPc from the plasma membrane occurs
constitutively in cultured cells and a large part of the protein
recycles back to the plasmalemma without degradation [17].
Initial experiments have shown the presence of PrPc in endo-
cytic organelles [17] and later the involvement of clathrin-
coated vesicles was proposed [18]. However, PrPc is present
in rafts at the plasma membrane where most GPI-anchored
proteins appear to accumulate [19] and may undergo caveo-
lar-like mechanism of internalization. Since PrPc lacks trans-
membrane domains to assist interactions with clathrin adapter
proteins, it has been proposed that PrPc internalization does
not depend on clathrin-mediated endocytosis [20] or that an-
cillary proteins are required [4,18].
In order to visualize PrPc tra⁄c, we [7] and others [21] have
tagged mouse or bovine PrPc with green £uorescent protein
(GFP). The GPI-anchored £uorescent fusion protein appears
to be functional [7,21]. One of the hallmarks of PrPc tra⁄c is
its copper-induced internalization [6,22]. We followed GFP-
PrPc tra⁄c in living neuronal cells and found that the £uo-
rescent protein is internalized from the plasma membrane and
accumulates at a perinuclear region in response to copper [7].
The localization of internalized GFP-PrPc is still under inves-
tigation, however one of the compartments labeled by the
£uorescent protein at steady state is the Golgi apparatus
[21]. We have also observed that part of the perinuclear label-
ing is co-localized with internalized transferrin, FM4-64 and a
Rab-5 mutant, all of which are markers of classical endocytic
organelles [23]. PrPc internalization mediated by copper de-
pends on the originally described N-terminal octarepeat do-
main [5] rather than on the newly described copper-binding
motif [24]. This methodology may provide novel information
on the physiological pathways followed by PrPc inside cells.
4. PrPc physiological function unsolved by generation of PrPc
null mice
In 1992 Charles Weissmann’s group [25] generated PrPc-
null mice and reported that PrPc expression is dispensable
for normal development and behavior. In agreement with
these results, we further demonstrated [26] that such animals
had normal performance in short- and long-term fear-moti-
vated memory, anxiety and exploratory behavior. Moreover,
alterations both in circadian activity and sleep were also de-
scribed [27].
The role of PrPc is still unclear even after the generation of
three additional strains of PrPc null mice. One of them, Npu,
showed normal development while the other two, Ngsk and
Rcm0 developed late onset ataxia (reviewed in [28]). These
apparent contradictory results were solved by cloning a gene
located 16 kb downstream from Prn-p gene, called Doppel,
which generates two major transcripts of 1.7 and 2.7 kDa, as
well as an unusual chimeric transcript generated by intergenic
splicing with Prn-p. Interestingly, the chimeric transcript is
up-regulated in strains of PrPc null mice that show ataxia,
but not in those with a normal phenotype, suggesting that
the overexpression of Doppel rather than the absence of
PrPc is the cause of neurodegeneration [28].
Taken together, these data suggest that animals without
PrPc develop normally and have normal behavior in most
of the tests applied. These results may be due to compensatory
mechanisms as previously described [25]. However, it may be
argued that the right test should be applied to ¢nd the altered
phenotype.
The generation of conditional PrPc-null mice would be im-
portant to solve questions regarding compensatory mecha-
nisms. However, an alternative approach is to acutely block
PrPc, for example by the use of speci¢c antibodies, such that
protein function is not compensated.
5. In vitro experiments show that PrPc mediates neuronal cell
adhesion, di¡erentiation and survival
Various PrPc-binding proteins have been identi¢ed, but
the role of most of these interactions remains to be established
(reviewed in [29]). Strong evidence for PrPc function derives
from its interaction with laminin [2,3] because binding of
the latter to its classical receptor integrins plays a pivotal
role in cell proliferation, di¡erentiation, migration and death
[30].
We found that PrPc is a high a⁄nity receptor for laminin,
with a binding site at the carboxy-terminal decapeptide
(RNIAEIKDI) of the laminin Q-1 chain [2]. This domain
had been shown to mediate neurite formation but the nature
of its cellular ligand was obscure [31]. Neurite extension elic-
ited by intact laminin was inhibited by anti-PrPc antibodies,
while that mediated by the Q-1 chain decapeptide was com-
pletely abolished. Furthermore, neurons from PrPc-null mice
grew fewer neurites on laminin than wild type animal cells,
and no neuritogenesis was induced by the Q-1 chain decapep-
tide [2]. Finally, we also found that the PrPc^laminin inter-
action a¡ects both neuronal cell adhesion and neurite main-
tenance [3].
PrPc is expressed in most tissues and laminin Q-1 chain is
the most conserved of all laminin types [30]. Thus, we predict
that their interaction may be important not only in the nerv-
ous system but in other tissues as well.
PrPc also interacts with the 37-kDa/67-kDa laminin recep-
tor, which may participate in the internalization of 20^50% of
the membrane-bound PrPc [32], indicating the need of other
components to mediate PrPc internalization. It is interesting
to note that both PrPc and laminin interact with the same
domain at the laminin receptor, suggesting that laminin re-
ceptor^PrPc binding excludes laminin receptor^laminin inter-
action [33]. On the other hand, the laminin receptor and PrPc
bind to distinct domains of laminin, in either the K1 [34] or
the Q-1 chains [2], respectively. These alternative associations
may be interpreted as combinatorial association events lead-
ing to various signal transduction pathways, and their biolog-
ical relevance needs to be addressed.
Cell culture experiments indicated that PrPc a¡ects neuro-
nal survival under stress. Copper-bound PrPc shows super-
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oxide dismutase activity [35], and PrPc-null cultured neurons
are more sensitive than wild-type neurons to oxidative stress
in vitro [36]. Thus, the loss of PrPc-mediated anti-oxidant
function may be involved in prion diseases [37]. Indeed, se-
rum-deprived PrPc-null mouse cell lines were more sensitive
than wild type cells to programmed cell death [38]. In addi-
tion, overexpression of PrPc in human primary neurons
protected against apoptosis induced by overexpressed Bax
[39].
We found that a PrPc-binding peptide, containing sequen-
ces found in the putative PrPc p66 ligand previously described
[4], partially prevented programmed cell death of undi¡eren-
tiated post-mitotic retinal cells (Chiarini et al., submitted for
publication). The same peptide both increased intracellular
cAMP, and activated the Erk pathway in the retina, but the
neuroprotective e¡ect required activity of cAMP-dependent
protein kinase (PKA) rather than MAP kinase (Chiarini et
al., submitted for publication). The mechanism by which
PrPc stimulates adenylyl cyclase remains to be investigated,
but activation of G-proteins by various GPI-anchored mole-
cules has been shown [40].
These data raise the intriguing possibility that PrPc may be
a neurotrophic receptor for p66. In combination with the loss
of direct anti-oxidant activity, depletion of PrPc would de-
prive nervous tissue of intracellular neuroprotective pathways,
thereby lowering the threshold for programmed cell death in
prion diseases [41].
Antibodies to PrPc lead to caveolin-dependent activation of
the Fyn tyrosine kinase in a neuroectodermal cell line, follow-
ing induction of neuron-like di¡erentiation [42]. Although
consistent with signaling through PrPc in membrane lipid
rafts, both the arti¢cial conditions and dependence on cross-
linking preclude conclusions regarding physiological roles of
PrPc.
6. A putative role for PrPc dysfunction in pathologies other
than classical prion diseases
With respect to neurological diseases involving excitotoxic-
ity and neuroplasticity, we recently found that PrPc-null mice
are more susceptible to acute seizures and kindling induced by
various protocols [43]. Since oxidative stress plays a role in
pathophysiology both during and after seizures [44], an im-
pairment of brain anti-oxidant defences in PrPc-null mice [45]
may play an important role in their lower threshold to seiz-
ures. Moreover, these animals showed changes in the activity
of ectonucleotidases (apyrase and 5P-nucleotidase) of neocor-
tical and hippocampal synaptosomes, that could result in low-
er levels of endogenous anti-convulsant adenosine in the syn-
aptic cleft [46].
Regarding human neurological and psychiatric illnesses, a
familial form of an atypical psychiatric disorder was associ-
ated with a higher prevalence of a PrPc gene mutation [47].
The relationship of these ¢ndings with the physiological roles
of PrPc remains to be elucidated.
Finally, protein and lipid oxidation in association with low-
er catalase activity are greatly increased in skeletal muscle,
heart, and liver of PrPc-null mice [45]. These data suggest
that PrPc may have an important role in oxidative stress
not only in the central nervous system but also in other or-
gans. If this is the case, the ‘physiological prion protein sys-
tem’ may be implicated not only in acute or chronic neuro-
logical and psychiatric diseases, but also with other human
illnesses, such as myocardial infarction (heart reperfusion in-
jury), hepatic failure and sepsis among others.
7. A PrPc-based multi-functional protein complex
The involvement of PrPc in protection against oxidative
Fig. 1. A multi-functional PrPc-based protein complex. PrPc interaction with laminin mediates neuronal adhesion and di¡erentiation. The bind-
ing of a peptide (dark blue) that mimics a PrPc putative ligand, p66, induces cell signaling and promotes cell survival. The complex PrPc^p66
may be formed between proteins either in the same or in distinct cells. Copper uptake by PrPc protects against oxidative stress, induces protein
internalization and may be involved with switching o¡ mechanisms. Laminin receptor seems to be involved with protein internalization and the
role of integrins is still under investigation.
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stress, cell adhesion, di¡erentiation, signaling and survival is
attributed to its interaction with copper, laminin and p66 (Fig.
1). PrPc is likely a part of a multi-component protein com-
plex, and due to its cellular localization it may connect signals
from the extracellular matrix to the intracellular milieu. PrPc
interaction with laminin induces cell adhesion and neuritogen-
esis, and a peptide that mimics PrPc^p66 binding mediates cell
survival. The role of copper in the internalization of PrPc can
be interpreted either as a mechanism of protection against
oxidative insults, or as a mechanism for switching o¡ elicited
signals. This complex organization and the contribution of
other proteins such as integrins and the laminin receptor
[32] in these processes merit further investigation. In conclu-
sion, the evidence for multiple functions of PrPc supports the
hypothesis that either depletion or mutations in the cellular
prion may lead to loss-of-function components in prion dis-
eases [48].
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